コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 idities, previous nonbiologic treatments for plaque psoriasis).
2 Trial of roflumilast cream for chronic plaque psoriasis.
3 en and adolescents worldwide are affected by plaque psoriasis.
4 placebo in patients with moderate-to-severe plaque psoriasis.
5 acebo in the treatment of moderate to severe plaque psoriasis.
6 XORA-PEDS) evaluated pediatric patients with plaque psoriasis.
7 olerated in patients with moderate-to-severe plaque psoriasis.
8 IL-17A for patients with moderate to severe plaque psoriasis.
9 was receiving Ixekizumab therapy for chronic plaque psoriasis.
10 avacitinib in adults with moderate-to-severe plaque psoriasis.
11 o tumour necrosis factor alpha inhibitors in plaque psoriasis.
12 is under investigation for the treatment of plaque psoriasis.
13 17) and has been approved for use in chronic plaque psoriasis.
14 mpared with other agents in the treatment of plaque psoriasis.
15 eatment study that included 14 patients with plaque psoriasis.
16 ults and adolescents with moderate-to-severe plaque psoriasis.
17 sicians to define on-treatment remission for plaque psoriasis.
18 hibitor, for treatment of moderate-to-severe plaque psoriasis.
19 TYK2 JH2 ligand deucravacitinib for treating plaque psoriasis.
20 eased for biologic medications used to treat plaque psoriasis.
21 ssessed the RORgammat inhibitor BI 730357 in plaque psoriasis.
22 cle in patients with mild to moderate AD and plaque psoriasis.
23 of tapinarof in patients with mild-to-severe plaque psoriasis.
24 ciated with the main genetic determinants of plaque psoriasis.
25 learance in patients with moderate-to-severe plaque psoriasis.
26 alimumab in patients with moderate-to-severe plaque psoriasis.
27 ng the endothelial function of patients with plaque psoriasis.
28 ars or older with moderate-to-severe chronic plaque psoriasis.
29 ts an evolving treatment strategy in chronic plaque psoriasis.
30 o and etanercept in the treatment of chronic plaque psoriasis.
31 umab in children and adolescents with severe plaque psoriasis.
32 hibitor, in patients with moderate-to-severe plaque psoriasis.
33 of patients with moderate-to-severe chronic plaque psoriasis.
34 es with the classic subtype of Western large plaque psoriasis.
35 ies, for the treatment of moderate-to-severe plaque psoriasis.
36 alimumab in patients with moderate-to-severe plaque psoriasis.
37 I 655066 in patients with moderate-to-severe plaque psoriasis.
38 option for patients with moderate-to-severe plaque psoriasis.
39 s a treatment for moderate-to-severe chronic plaque psoriasis.
40 ntibody, in patients with moderate-to-severe plaque psoriasis.
41 valuated in patients with moderate-to-severe plaque psoriasis.
42 I-s, saSPI-s, and SPI-p in 100 patients with plaque psoriasis.
43 efficacious treatment for moderate-to-severe plaque psoriasis.
44 ody, for the treatment of moderate-to-severe plaque psoriasis.
45 dren and adolescents with moderate-to-severe plaque psoriasis.
46 dren and adolescents with moderate-to-severe plaque psoriasis.
47 er polymorphisms of the MIF gene and chronic plaque psoriasis.
48 easures, in patients with moderate to severe plaque psoriasis.
49 cept, a TNF antagonist, for the treatment of plaque psoriasis.
50 disease expression in patients with chronic plaque psoriasis.
51 in pivotal phase III trials in patients with plaque psoriasis.
52 s are present in the skin lesions of chronic plaque psoriasis.
53 most effective systemic medications to treat plaque psoriasis?
54 3.9] years in the vehicle group) and 34 with plaque psoriasis (20 men [58.8%]; mean [SD] ages, 51.8 [
55 le participants were 12 years and older with plaque psoriasis affecting up to 25% of the scalp and bo
57 ed lesional skin of 13 patients with chronic plaque psoriasis and 12 patients with other inflammatory
58 the general population in Tromso with active plaque psoriasis and 25-hydroxyvitamin D (25[OH]D) level
59 89 individuals with mild-to-moderate chronic plaque psoriasis and 54 without psoriasis, recruited at
61 nd FAS, were decreased in both Western large plaque psoriasis and psoriasis with accompanying arthrit
63 s first line treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis, and further ag
64 tekinumab trial suggesting efficacy for both plaque psoriasis and psoriatic arthritis, our case serie
65 ed 1106 eligible adult patients with chronic plaque psoriasis and randomly assigned them to the four
66 icipants were adults with moderate to severe plaque psoriasis and received ustekinumab in a lead-in p
68 and active plaque psoriasis than in chronic plaque psoriasis and sebopsoriasis; i.e., the extent of
69 t guselkumab may be an effective therapy for plaque psoriasis and that control of psoriasis can be ac
71 nty-eight UK caucasian patients with chronic plaque psoriasis, and a control panel of 401 UK caucasia
72 targeting LFA-1 for the treatment of chronic plaque psoriasis, and natalizumab (Tysabri/Antegren) tar
75 rodalumab in Treatment of Moderate to Severe Plaque Psoriasis], and -3 [Efficacy and Safety of Brodal
77 ion, we defined Asian small and intermediate plaque psoriasis as psoriasis subtypes and compared thei
78 (>=12 years of age) with moderate-to-severe plaque psoriasis, as defined by all the following: a tot
80 older, had a confirmed diagnosis of chronic plaque psoriasis at least 6 months before baseline (rand
82 r first-line treatment of moderate to severe plaque psoriasis because of their efficacy in treating i
83 This economic evaluation showed that for plaque psoriasis biologics, using an EF approach to nego
84 ars or older with moderate-to-severe chronic plaque psoriasis (body surface area involvement >/=10%,
85 d interleukin-12 are efficacious in treating plaque psoriasis but must be delivered via intravenous o
86 h 16 weeks in reducing symptoms and signs of plaque psoriasis but was associated with a higher freque
87 700841 improves clinical symptoms of chronic plaque psoriasis by inhibition of proinflammatory cytoki
88 sitizing agent protoporphyrin IX in areas of plaque psoriasis by monitoring of the fluorescence emiss
89 with type 1 (onset before age 40 y) chronic plaque psoriasis compared to healthy controls and also m
90 ponse in the treatment of moderate to severe plaque psoriasis compared with patients who received pla
91 2, 2020, 666 adults with moderate to severe plaque psoriasis completed the PSSD daily throughout the
92 3 to January 2020 from patients with chronic plaque psoriasis consecutively attending the outpatient
93 hat blood samples from patients with chronic plaque psoriasis contained significantly higher titers o
94 te AD (covering 5%-20% body surface area) or plaque psoriasis (covering 5%-15% body surface area).
96 respectively) adults with moderate-to-severe plaque psoriasis diagnosed for at least 26 weeks (body-s
98 8 years or older, had a diagnosis of chronic plaque psoriasis for at least 6 months before baseline,
99 ty trial, adult patients with chronic stable plaque psoriasis (for >/=12 months) who were candidates
100 males [64%]) with SoC and moderate to severe plaque psoriasis from August 2022 to March 2023 to evalu
101 o-thirds of patients with moderate-to-severe plaque psoriasis harbour CD4(+) and/or CD8(+) T cells sp
104 A alone, in patients with moderate-to-severe plaque psoriasis have not been extensively examined.
105 alimumab in patients with moderate-to-severe plaque psoriasis have not been extensively examined.
106 ly assigned patients with moderate-to-severe plaque psoriasis in a 1:1:1 ratio to receive subcutaneou
107 lind trial, we randomly assigned adults with plaque psoriasis in a 1:1:1 ratio to use roflumilast 0.3
108 rapy resulted in significant improvements in plaque psoriasis in subjects with moderate-to-severe dis
109 lacebo and Ustekinumab in Moderate to Severe Plaque Psoriasis in Subjects]) participated in a mechani
111 ly assigned patients with moderate-to-severe plaque psoriasis, in a 1:1 ratio, to receive bimekizumab
112 rapeutic advancements for moderate to severe plaque psoriasis include biologics that inhibit TNF-alph
123 ated longitudinal transcriptomic profiles of plaque psoriasis lesions from patients enrolled in a cli
124 design and included 38 patients with chronic plaque psoriasis measuring less than or equal to 100 cm2
125 and limb defects] syndrome, n = 2) and from plaque psoriasis (n = 2) demonstrate significantly reduc
126 cohort study including patients with chronic plaque psoriasis (n = 6501) being treated with biologic
130 vehicle control in reducing the severity of plaque psoriasis over a period of 12 weeks but was assoc
131 les from 81 patients with moderate-to-severe plaque psoriasis participating in 2 different studies (a
132 07038124, 9 [25.0%]; vehicle, 9 [26.5%]) and plaque psoriasis (PF-07038124, 3 [17.6%]; vehicle, 6 [35
133 g/kg in children and adolescents with severe plaque psoriasis provided significant improvements in PA
134 th AGEP, GPP, palmoplantar pustulosis (PPP), plaque psoriasis (PSO), and nonpustular cutaneous advers
136 ed 18 years or older with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index [PAS
137 COVID-19 in a large sample of patients with plaque psoriasis receiving biologic therapies compared w
139 Western large plaque psoriasis, Asian small plaque psoriasis revealed limited psoriasis spreading, b
140 t a subpopulation of CD4+ T cells in chronic plaque psoriasis skin lesions produces interferon-gamma
141 ks is associated with improvement in chronic plaque psoriasis; some patients have a sustained clinica
142 atment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects], -2 [P3 Study Brodalumab in T
145 ore important in the pathogenesis of chronic plaque psoriasis than has previously been recognized, an
146 s more disrupted in erythrodermic and active plaque psoriasis than in chronic plaque psoriasis and se
147 eport 4 cases of ustekinumab monotherapy for plaque psoriasis that resulted in disabling flares of kn
149 ekizumab in patients with moderate to severe plaque psoriasis, the effects of treatment withdrawal, a
151 ough the disease can present with concurrent plaque psoriasis, TNF and IL-17/IL-23 inhibitors show li
152 ly assigned patients with moderate-to-severe plaque psoriasis to receive JNJ-77242113 at a dose of 25
153 142 patients with chronic moderate-to-severe plaque psoriasis to receive subcutaneous injections of 1
154 A-1 (efalizumab; Raptiva for severe forms of plaque psoriasis) to prevent extravasation of inflammato
156 eucravacitinib in phase 3 moderate-to-severe plaque psoriasis trials, with similar adverse event rate
157 trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment wi
158 es of psoriasis are recognised, with chronic plaque (psoriasis vulgaris) accounting for 90% of cases.
159 isease management, on-treatment remission in plaque psoriasis was defined as patients maintaining a B
160 onsensus process, on-treatment remission for plaque psoriasis was defined as patients maintaining a B
161 hase 4 study, adults with moderate-to-severe plaque psoriasis were assigned 1:1 to receive IXE or GUS
162 r 3,523 biologic-naive patients with chronic plaque psoriasis were compared using survival analysis t
166 ed 18 years or older with moderate to severe plaque psoriasis were stratified by region and previous
168 matory cytokines were lower in Western large plaque psoriasis, whereas T cells and dendritic cells in
169 r adults (>18 years) with moderate to severe plaque psoriasis who are candidates for phototherapy or
170 asian male with treatment-refractory chronic plaque psoriasis who developed new onset diarrheal illne
171 was collected from 374 patients with chronic plaque psoriasis who had been treated with methotrexate.
172 atients (aged >/=4 to <18 years) with severe plaque psoriasis who had not responded to topical therap
173 t of biologic medication-naive patients with plaque psoriasis who initiated a biologic medication fro
175 gister for adults treated with biologics for plaque psoriasis who were seen at multicenter dermatolog
177 is effective in treatment of limited chronic plaque psoriasis with a satisfactory safety profile.
178 dults with PPP (11 patients) or palmoplantar plaque psoriasis with pustules (10 patients) treated at
179 lmoplantar pustulosis (PPP) and palmoplantar plaque psoriasis with pustules remain challenging to tre
180 ling approach for treating PPP, palmoplantar plaque psoriasis with pustules, and SAPHO syndrome.